CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory AssetGlobeNewsWire · Oct 14, 2026
CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug DiscoveryGlobeNewsWire · Sep 29, 2026
CDT Equity Inc. Announces Reverse Stock SplitGlobeNewsWire · Sep 25, 2026
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and VitiligoGlobeNewsWire · Sep 18, 2026
CDT Highlights Sarborg's Application of Signature Intelligence and Quantum Computing Models to Mental HealthGlobeNewsWire · Sep 10, 2026
CDT Provides Capital Update and Confirms No Nasdaq DeficienciesGlobeNewsWire · Sep 2, 2026CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health.